• CENTRE FOR COMMERCIALIZATION OF CANCER IMMUNOTHERAPY - C3I



 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

C3i’s Biomarker and Diagnostic unit now offers TCR-beta sequencing services

November 13th, 2017

The Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

C3i participates to the challenge Cycle for a Cure!

September 30th, 2017

The 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

IRICoR and C3i Announce Partnership to Identify novel Tumor-Specific Antigens (TSAs)

April 4th, 2017

Novel Approach to Identifying TSAs based on a unique mass spectrometry approach discovered at IRIC combined with expertise in genomic sequencing and clinical validation from C3i

 zehfcnamoziehfnpùoazejfpoezaj,fxùpiaenzgùiqemlfr

Government of Canada invests in research commercialization

February 12th, 2016

$29 million investment in two commercialization centres will accelerate Canadians’ access to innovative cancer immunotherapies and natural products